ADMA Biologics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? ADMA Biologics Inc trades at $9.85 (market cap $2.22B), while Vanguard Information Technology Index Fund ETF trades at $121.82. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VGT | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | — |
52-Week High | $20.38 | $125.77 |
52-Week Low | $7.60 | $83.59 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
VGT trades at $121.85, up 1.33% with strong bullish momentum from moving averages. The ETF benefits from institutional accumulation and positive AI infrastructure exposure. Technical indicators show RSI_6 at 82.74 suggesting overbought conditions while ADX signals strong trend strength. Recent news highlights institutional buying sprees and Microsoft's earnings boost to tech ETFs.
Outlook remains positive given institutional confidence and AI-driven growth, though concentration risk and overbought technicals warrant caution. The pure-tech focus has outperformed broader tech ETFs historically, but semiconductor volatility presents near-term headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →